Efficacy and Safety of Firsekibart in Treatment of Active Systemic Juvenile Idiopathic Arthritis: A Randomized Phase 2 Study

Abstract Introduction Systemic juvenile idiopathic arthritis (sJIA) is an autoinflammatory disorder that impacts children aged ≤ 16 years. This study evaluated the efficacy and safety of firsekibart, a fully human anti-IL-1β monoclonal antibody, in children with active sJIA. Methods This multicenter...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Caifeng Li, Junmei Zhang, Haiguo Yu, Meiping Lu, Sirui Yang, Cuihua Liu, Ping Zeng, Bo Zhao, Xiaoqing Li, Wenjie Zheng, Yue Du, Wei Zhang, Zhihui Li, Xiufen Hu, Jianming Lai, Qian Xu, Xu Zhang, Xianyang Wang, Palasaiti Adili, Wei Qu
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Adis, Springer Healthcare 2026-03-01
Rangatū:	Rheumatology and Therapy
Ngā marau:	Firsekibart Interleukin-1β (IL-1β) Phase 2 study Systemic juvenile idiopathic arthritis
Urunga tuihono:	https://doi.org/10.1007/s40744-026-00830-9
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!